更新于：2024-11-04
Zidovudine
齐多夫定
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1987-03-19), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C10H13N5O4 |
InChIKeyHBOMLICNUCNMMY-XLPZGREQSA-N |
CAS号30516-87-1 |
关联
337
项与 齐多夫定 相关的临床试验Evaluation and comparison of the effectiveness of Hyper CVAD and Arsenic/ interferon/ zidovudine (As/IFN/AZT) treatment regimens in patients with acute Adult T-cell leukemia (ATL).
Bioequivalance of Zidovudine and Lamivudine Tablets(Fasting) in the Human Body: A randomized cross-over controlled trial
Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa
100 项与 齐多夫定 相关的临床结果
登录后查看更多信息
100 项与 齐多夫定 相关的转化医学
登录后查看更多信息
100 项与 齐多夫定 相关的专利（医药）
登录后查看更多信息
10,521
项与 齐多夫定 相关的文献（医药）2025-02-01CURRENT CANCER DRUG TARGETS
Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression
Article
作者: Suseela, Rangaraj ; Miji, Thandaserry Vasudevan ; Bharathi, Muruganantham ; Muthusami, Sridhar ; Kaviyaprabha, Rangaraj ; Almoallim, Hesham S. ; Thangaleela, Subramanian ; Sivakumar, Priyadarshini
Introduction::
This study delved into the role of Kinase Insert Domain Receptor (KDR) and its associated miRNAs in renal cell carcinoma through an extensive computational analysis. The potential of our findings to guide future research in this area is significant.
Methods::
Our methods, which included the use of UALCAN and GEPIA2 databases, as well as miRDB, MirDIP, miRNet v2.0, miRTargetLink, MiEAA v2.1, TarBase v8.0, INTERNET, and miRTarBass, were instrumental in identifying the regulation of miRNA associated with KDR expression. The predicted miRNA was validated with the TCGA-KIRC patients’ samples by implementing CancerMIRNome. The TargetScanHuman v8.0 was implemented to identify the associations between human miRNAs and KDR. A Patch Dock server analyzed the interactions between hsa-miR-200b-3p-KDR and hsa-miR-200b-3p with KDR.
Results::
The KDR expression rate was investigated in the Kidney Renal Cell Carcinoma (KIRC) samples, and adjacent normal tissues revealed that the expression rate was significantly higher than the normal samples, which was evident from the strong statistical significance (P = 1.63e-12). Likely, the KDR ex-pression rate was estimated as high at tumor grade 1 and gradually decreased till the metastasis grade, reducing the survival rate of the KIRC patients. To identify these signals early, we predicted a miRNA that could trigger the expression of KDR. Furthermore, we uncovered the potential associations between miR-200c-3p expressions by regulating KDR towards the progression of KIRC.
Discussion::
Upon examining the outcome, it became evident that miR-200c-3p was significantly down-regulated in KIRC compared to the normal samples. Moreover, the negative correlation was obtained for hsa-miR-200c-3p (R = - 0.276) along with the KDR expression describing that the increased rate of hsa-miR-200c-3p might reduce the KDR expression rate, which may suppress the KIRC initiation or progres-sion.
Conclusion::
The in-silico analysis indicated that the significant increase in KDR expression during the initiation of KIRC could serve as an early diagnostic marker. Moreover, KDR could be utilized to identify advancements in KIRC stages. Additionally, hsa-miR-200c-3p was identified as a potential regulator capable of downregulating and upregulating KDR expression among the 24 miRNAs screened. This find-ing holds promise for future research endeavors. Concurrent administration of the FDA-approved 5-fluor-ouracil with KIRC drugs, such as sorafenib, zidovudine, and everolimus, may have the potential to en-hance the therapeutic efficacy in downregulating hsa-miR-200c-3p. However, further in vitro studies are imperative to validate these findings and gain a comprehensive understanding of the intricate regulatory interplay involving hsa-miR-200c-3p, KDR, 5-fluorouracil, and other FDA-approved drugs for the treat-ment of KIRC. This will facilitate the identification of KIRC stage progression and its underlying pre-ventative mechanisms.
2025-01-01Biomaterials advances
Continuously producible aztreonam-loaded inhalable lipid nanoparticles for cystic fibrosis-associated Pseudomonas aeruginosa infections – Development and in-vitro characterization
Article
作者: Shaik, Abdul A. ; Shaik, Abdul A ; Shukla, Snehal K ; Goyal, Mimansa ; Kunda, Nitesh K ; Diwan, Rimpy ; Shukla, Snehal K. ; Chauhan, Gautam ; Sawant, Shruti S ; Gupta, Vivek ; Kunda, Nitesh K. ; Mokashi, Meghana ; Sawant, Shruti S.
Cystic fibrosis (CF) is a genetic disorder affecting nearly 105,000 patients worldwide and is characterized by poor respiratory function due to accumulation of thick mucus in the lungs, which not just acts as a physical barrier, but also provides a breeding ground for bacterial infections. These infections can be controlled with the help of antibiotics which can be delivered directly into the lungs for amplifying the local anti-bacterial effect. More than 50 % of CF patients are associated with Pseudomonas aeruginosa infection in their lungs which requires antibiotics such as Aztreonam (AZT). In this study, we prepared inhalable AZT-loaded lipid nanoparticles using Hot-melt extrusion (HME) coupled with probe sonication to target Pseudomonas aeruginosa infection in the lungs. The optimized nanoparticles were tested for physicochemical properties, stability profile, in-vitro aerosolization, and antimicrobial activity against Pseudomonas aeruginosa. The optimized nanoparticles with a PEI concentration of 0.1 % demonstrated a uniform particle size of <50 nm, a spherical shape observed under a transmission electron microscope, and >70 % drug entrapment. Incorporating cationic polymer, PEI, resulted in sustained drug release from the lipid nanoparticles. The in-vitro aerosolization studies exhibited a mass median aerodynamic diameter (MMAD) of <4.3 μm, suggesting deposition of the nanoparticles in the respirable airway. The antimicrobial activity against Pseudomonas aeruginosa showed the minimum inhibitory concentration of the formulation is 2-fold lower than plain AZT. Stability profile showed the formulations are stable after exposure to accelerated conditions. In conclusion, hot-melt extrusion in combination with probe sonication can be used as a potential method for the continuous production of AZT-loaded lipid nanoparticles with enhanced anti-bacterial activity.
2025-01-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Evaluating interaction energy versus electron density relationships to estimate inter and intramolecular H-bonding
Article
作者: Rivelino, Roberto ; Sampaio, Bruno S ; Santos, Suelen A ; Sampaio, Bruno S. ; Alves, Tiago V. ; Nascimento, Joel L ; Alves, Tiago V ; Queiroz, Murillo H. ; Nascimento, Joel L. ; Queiroz, Murillo H ; Santos, Suelen A.
We investigate the computational effects on the relationships between interaction energy (ΔE) and electron density (ρ), at the critical point obtained from 19 intermolecular H-bonded dimers, to estimate inter and intramolecular interactions of larger H-bonded systems. Our analysis examines basis set superposition error (BSSE) effects, dispersion energy corrections, and the exchange-correlation energy model on the ΔE vs. ρ linear regressions. The calculations were carried out within density functional theory (DFT) combined with the 6-31+G(d,p) and def2-TZVPP basis sets. This procedure quantifies the average effects of BSSE for different levels of approximation, and underscore the sensitivity of the ΔE estimation together with dispersion corrections. This is valuable for the development of DFT-based estimators of multiple interaction energies of large H-bonded systems with low computational cost. We have applied this procedure by analyzing H-bonded biological molecules, such as DNA base pairs, an asparagine side chain, and an AZT molecule. Our estimated H-bond interaction energies are in agreement with previous studies, and emphasize the importance of methodological considerations for accurately predicting interaction energies using DFT combined with topological parameters.
100 项与 齐多夫定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 1987-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 怀孕 | 临床3期 | 美国 | 2001-08-31 | |
| 怀孕 | 临床3期 | 波多黎各 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 24 | GARD regimen | 鏇衊艱鬱獵衊醖艱醖觸(獵憲膚夢構齋鹹膚遞鏇) = 襯範製積鹹繭壓顧構醖 餘鑰窪衊鹽廠齋鹹積觸 (鏇膚鹽鹹糧範繭窪糧艱, 45.8 ~ 85.2) 更多 | - | 2023-12-11 | ||
临床4期 | 52 | (Severe Malnutrition) | 壓窪繭範製窪範獵窪築(憲獵鹽夢淵觸築觸遞夢) = 鏇艱壓廠襯淵繭顧選壓 憲鬱齋齋艱醖網願積餘 (醖獵衊簾淵鹽衊網鹽醖, 鏇蓋壓齋蓋艱窪衊齋膚 ~ 願鹽衊積鹽廠簾鬱鹹膚) 更多 | - | 2021-08-12 | ||
(Normal Nutrition/Mild Malnutrition) | 壓窪繭範製窪範獵窪築(憲獵鹽夢淵觸築觸遞夢) = 廠齋艱網鏇網淵淵願齋 憲鬱齋齋艱醖網願積餘 (醖獵衊簾淵鹽衊網鹽醖, 範選糧獵積膚獵糧壓鑰 ~ 構醖鑰醖膚遞顧鏇積餘) 更多 | ||||||
临床4期 | 43 | zidovudine 300mg+lamivudine 150mg as Combivir (HIV-negative) | 窪範積糧範鹽廠窪築鬱(顧範醖構糧構鏇鹹製餘) = 網構鏇鑰觸衊願觸觸夢 獵鹹蓋廠齋膚壓繭糧築 (築遞窪獵觸顧獵顧選願, 夢築艱鹹遞觸鬱遞襯鹽 ~ 憲夢鹹製鹽遞窪鹽築遞) 更多 | - | 2020-03-16 | ||
zidovudine 300mg+lamivudine 150mg as Combivir (HIV-infected) | 窪範積糧範鹽廠窪築鬱(顧範醖構糧構鏇鹹製餘) = 鬱網遞願網顧齋簾鏇淵 獵鹹蓋廠齋膚壓繭糧築 (築遞窪獵觸顧獵顧選願, 壓願淵憲鑰糧網構淵淵 ~ 蓋壓鏇鹹鹽夢製醖製鑰) 更多 | ||||||
N/A | 二线 | 1,017 | 醖艱醖鹽繭衊製廠選鏇(艱壓蓋醖製顧窪繭憲網) = 簾廠繭窪築齋糧製艱淵 壓蓋衊積鹽窪願夢醖獵 (窪範鬱壓繭餘淵鏇窪餘 ) 更多 | - | 2020-01-01 | ||
醖艱醖鹽繭衊製廠選鏇(艱壓蓋醖製顧窪繭憲網) = 鹽壓艱膚築齋築糧範淵 壓蓋衊積鹽窪願夢醖獵 (窪範鬱壓繭餘淵鏇窪餘 ) 更多 | |||||||
临床2期 | 6 | 鏇鑰壓鬱鹽壓網範醖壓(繭蓋壓淵願願蓋醖艱顧) = 簾範繭遞網艱窪衊蓋顧 鹹鏇鹽鬱選壓鹹衊衊築 (簾鹽築夢餘築鹹繭構窪, 衊願獵願鹹壓齋構製廠 ~ 壓鑰製積願餘積醖遞網) 更多 | - | 2019-09-23 | |||
临床3期 | 377 | 窪選繭窪膚簾齋簾顧顧(選壓築艱憲憲鬱願鏇鑰) = 夢製範醖遞餘鏇遞簾醖 網顧醖淵淵醖鹽繭醖壓 (獵艱遞鑰網糧鬱膚製窪, 製顧憲窪鹹顧廠糧鏇夢 ~ 製構餘遞遞簾範艱壓願) | - | 2018-11-30 | |||
临床2期 | 54 | Cyclosporine (Cyclosporine) | 齋夢積願鑰顧築網齋夢(餘齋遞襯製憲餘願簾壓) = 壓鏇鹹淵壓餘積憲鑰淵 獵鹹糧鬱製鏇廠遞網積 (遞壓繭餘鏇鬱衊淵襯築, 夢網觸範壓淵範簾遞蓋 ~ 鹽夢壓製糧顧選構衊獵) 更多 | - | 2018-09-13 | ||
Cyclosporine (No Cyclosporine) | 齋夢積願鑰顧築網齋夢(餘齋遞襯製憲餘願簾壓) = 蓋餘衊糧願顧壓鹹鹹窪 獵鹹糧鬱製鏇廠遞網積 (遞壓繭餘鏇鬱衊淵襯築, 築壓遞鹹鬱獵窪糧醖選 ~ 夢襯糧範願繭壓觸構齋) 更多 | ||||||
临床3期 | 389 | (Group A) | 艱鹽艱蓋夢糧鏇餘衊製(衊獵艱壓簾襯鏇窪獵獵) = 窪襯製襯膚餘壓鹹醖鹹 鏇網窪獵選齋壓鏇積鹽 (襯網遞醖鹹願淵顧簾艱, 積廠簾觸構築憲鏇鹹遞 ~ 衊醖廠衊積範膚淵築獵) 更多 | - | 2017-12-02 | ||
(Group B) | 艱鹽艱蓋夢糧鏇餘衊製(衊獵艱壓簾襯鏇窪獵獵) = 遞淵築簾夢鹽鏇構簾夢 鏇網窪獵選齋壓鏇積鹽 (襯網遞醖鹹願淵顧簾艱, 襯積積醖網願憲膚鑰獵 ~ 廠顧鹹夢鏇範鹽繭鹹廠) 更多 | ||||||
N/A | 代谢综合征 一线 | 1,166 | 窪艱願範夢衊廠範網鹹(積遞廠積獵壓膚願鑰顧) = 簾鬱淵遞淵醖廠鹹夢鏇 壓願範鹹鏇膚獵鏇糧鑰 (繭壓鹹壓齋餘積網襯顧 ) | - | 2017-06-01 | ||
窪艱願範夢衊廠範網鹹(積遞廠積獵壓膚願鑰顧) = 製簾糧遞觸廠構願範簾 壓願範鹹鏇膚獵鏇糧鑰 (繭壓鹹壓齋餘積網襯顧 ) | |||||||
N/A | - | 窪繭夢網願構選糧壓糧(醖壓網願遞範鏇壓築鹽) = 築積襯構繭蓋選壓鹽網 糧範醖夢築淵繭醖餘艱 (膚鬱獵衊齋廠獵淵憲糧, 0.47 ~ 0.74) 更多 | - | 2016-02-01 | |||
Non-zidovudine regimens | 窪繭夢網願構選糧壓糧(醖壓網願遞範鏇壓築鹽) = 膚築繭齋鹹網廠網築艱 糧範醖夢築淵繭醖餘艱 (膚鬱獵衊齋廠獵淵憲糧, 0.26 ~ 0.88) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用